SCHEDULE: T. Rowe Price Discloses 16.8% Stake in Apogee Therapeutics

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 16.8% in Apogee Therapeutics Inc. as of March 31, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, indicating a significant ownership stake in Apogee Therapeutics Inc.
• The filing, dated April 8, 2026, reflects an aggregate of 10,291,220 shares beneficially owned, representing 16.8% of the class.
• This ownership includes sole voting power over 9,762,311 shares and sole dispositive power over 10,291,220 shares.
• The filing is an amendment (Amendment No. 1) to a previous filing.
• T. Rowe Price Investment Management, Inc. is identified as an investment adviser and a parent holding company.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant institutional confidence from a major asset manager, but provides no direct operational or financial updates from the company itself.

Positives

• Significant institutional ownership by a reputable investment firm (T. Rowe Price) can signal confidence in the company's long-term prospects.
• The substantial stake (16.8%) suggests a strong conviction in Apogee Therapeutics' value proposition.
• The filing confirms that the shares were acquired in the ordinary course of business, implying a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not contain specific financial performance data for Apogee Therapeutics, making it difficult to assess the company's current health.
• The nature of the filing (Schedule 13G) indicates a passive investment, meaning T. Rowe Price is not actively seeking to control or influence the company's management.

Risks

• The concentration of ownership with a single large investor could potentially influence market perception and trading dynamics.
• While not explicitly stated as a risk in this filing, significant institutional ownership can sometimes lead to increased volatility if the investor decides to divest a large portion of their holdings.

Future Outlook

This filing does not contain forward-looking statements or guidance from Apogee Therapeutics Inc. It solely reports on the ownership stake of T. Rowe Price Investment Management, Inc.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• Ellen York, Vice President of T. Rowe Price Investment Management, Inc., certified that the information is true, complete, and correct.

Industry Context

StockSavvy.ai notes that significant institutional filings like this for biotechnology companies often reflect investor sentiment towards the company's pipeline and clinical trial progress. Apogee Therapeutics operates in the competitive biotechnology sector, where substantial investment is crucial for research and development.

Stakeholder Impact

• Shareholders: May view the increased stake by a prominent investor as a positive signal, potentially influencing share price. However, the passive nature of the filing means no immediate management influence is expected.
• Management: The filing does not directly impact management's operational control, as T. Rowe Price is not seeking to influence control.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• Monitor future filings from T. Rowe Price Investment Management, Inc. for any changes in their ownership stake.
• Observe any potential strategic implications or market reactions to this increased institutional holding.

Key Dates

Recommendation

This filing is primarily an ownership disclosure and does not contain operational or financial performance data for Apogee Therapeutics. While significant institutional interest is noted, a 'hold' recommendation is appropriate pending further company-specific updates on its pipeline and financial health.

Keywords

Apogee Therapeutics, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals